Home » Topics » Substance use and poisoning, BioWorld Science

Substance use and poisoning, BioWorld Science
RSS

NIDA to fund phase II methamphetamine addiction trial of MN-166

Sep. 5, 2012

Orexo plans NDA for sublingual buprenorphine/naloxone product

Aug. 22, 2012

FDA approves new dosages of sublingual film for opioid dependence

Aug. 21, 2012

Pivotal BEMA-buprenorphine/naloxone trial advances

Aug. 21, 2012

Buprenorphine/naltrexone combination evaluated in experimental cocaine dependence

Aug. 20, 2012

Study identifies role of thrombomodulin-aPC pathway in radioprotection

Aug. 7, 2012

Antinicotine gene therapy as a novel approach to nicotine addiction

July 20, 2012

Soligenix receives grant for acute radiation syndrome therapy

July 18, 2012

Topline results expected early from phase IIb study of vigabatrin

July 16, 2012

BioDelivery Sciences reports on BEMA-buprenorphine/naloxone study

July 4, 2012

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 15, 2026.
MMP inhibitors divulged in Accure Therapeutics patent
BioWorld Science
Accure Therapeutics has reported new oligopeptide derivatives acting as matrix metalloproteinase-2 (MMP-2) and MMP-9 inhibitors. As such, they are described as...
News in brief
BioWorld Asia
BioWorld Asia briefs for April 14, 2026
Selective CBL-B inhibitor with improved safety profile disclosed
BioWorld Science
CBL-B is a RING-type E3 ubiquitin ligase that acts as a negative regulator of T-cell activation, contributing to immune homeostasis by limiting excessive immune...
MSD discloses new HCN1/2 blockers
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has synthesized new indazole derivatives acting as potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 1...